#Rapt therapeutics stock news trial
The ongoing COVID-19 pandemic has materially affected and could continue to impact our operations, including at our headquarters in the San Francisco Bay Area and at our clinical trial sites, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.FLX475, RPT193 or other future drug candidates may not demonstrate the safety and efficacy necessary to support further clinical development or commercial viability.FLX475 and RPT193 are in clinical development, which may fail or suffer delays that materially and adversely affect their commercial viability.We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock. We are a clinical stage biopharmaceutical company with a history of losses.By accessing the web site, a user agrees not to redistribute the information found therein.
![rapt therapeutics stock news rapt therapeutics stock news](https://www.newsquantified.com/pic/ssp/CRSP.jpeg)
Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. It can identify business that are better managed or not.ĭata and information is provided for informational purposes only, and is not intended for trading purposes. Acceptable solvency ratios will vary from industry to industry.Įfficiency measures the strength of a company's return on invested capital. Solvency measures a company's ability to meet its long-term debts. Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. it tells investors how fast a company is growing. Growth measures the growth of both a company's revenue and net income. The current width of the bands does not suggest anything about the future direction or movement of prices.įri, Immix Biopharma Receives Tepid Wall Street Reception in IPO Debut - dot.LA Tue, Billionaire James Simons Family Office is Investing in Artificial Intelligence - Bloomberg Tue, RAPT Therapeutics Appoints Industry Veteran Lori Lyons-Williams to its Board of Directors - GlobeNewswire Mon, RAPT Therapeutics Announces Upcoming Oral Presentation of - GlobeNewswire Thu, RAPT Therapeutics highlights topline results from Phase 1b RPT193 atopic dermatitis study - Seeking Alpha Thu, RAPT Therapeutics Announces Late-Breaking Oral Presentation - GlobeNewswire However a short term pullback inside the band is likely.Bollinger Bands are 14.4% wider than normal. If price is in a uptrend band this upward trend in price might continue. From the relationship between price and moving averages we can see that: This stock is NEUTRAL in short-term and NEUTRAL in mid-long term.RAPT has closed above the upper band by 16.5%. Short term moving average is currently below mid-term AND below long term moving averages. Price and moving averages has closed above its Short term moving average. Price, moving averages and Bollinger Bands Stoxline posted a BUY today, same as yesterday. Its RPT193 drug candidate, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells), into allergically-inflamed tissues. Its lead oncology drug candidate FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory Treg cells into tumors. Its drug discovery and development engine has identified CCR4 as a drug target that potentially has broad applicability in oncology and inflammatory diseases.
![rapt therapeutics stock news rapt therapeutics stock news](https://s3.amazonaws.com/images.investorsobserver.com/wp-content/uploads/2020/08/11160731/Research-Scientist-Concept.jpg)
The company has discovered and advanced two drug candidates FLX475 and RPT193, which is engaged in targeting C-C motif chemokine receptor 4 (CCR4). The company is developing selective small molecules designed to modulate the critical immune responses underlying these diseases.
![rapt therapeutics stock news rapt therapeutics stock news](https://cdn.snapi.dev/images/v1/6/k/press6-866676.jpg)
The company is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company is headquartered in South San Francisco, California and currently employs 64 full-time employees. operates as a clinical stage immunology-based biopharmaceutical company.